Joseph C. Papa - Mar 12, 2025 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role: President and CEO, Director
Signature: /s/ Richard S. Lindahl, Attorney-in-fact
Stock symbol: EBS
Transactions as of: Mar 12, 2025
Transactions value $: $0
Form type: 4
Date filed: 3/12/2025, 06:12 PM
Previous filing: Mar 10, 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EBS	Employee Stock Options (Right to Buy)	Award	$0	+250K	+24.21%	$0.00	1.28M	Mar 12, 2025	Common Stock	250K	$2.33	Direct	F1
transaction	EBS	Employee Stock Options (Right to Buy)	Award	$0	+250K	+19.49%	$0.00	1.53M	Mar 12, 2025	Common Stock	250K	$2.33	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of an award of performance stock options granted under the company's Inducement Plan. These performance stock options vested in one annual installment on the day prior to the first anniversary of the date of grant based on the achievement of the $5 and $10 stock price performance hurdles as described in Mr. Papa's executive employment agreement dated February 19, 2024 (the "Papa Employment Agreement") and as certified by the company's Compensation Committee on February 12, 2025. Pursuant to the award, there remains 250,000 unvested performance stock options that are subject to a $15 stock price performance hurdle as described in the Papa Employment Agreement. Each performance stock option represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc. at the exercise price.

Content

Consists of an award of performance stock options granted under the company's Inducement Plan. These performance stock options vested in one annual installment on the day prior to the first anniversary of the date of grant based on the achievement of the $5 and $10 stock price performance hurdles as described in Mr. Papa's executive employment agreement dated February 19, 2024 (the "Papa Employment Agreement") and as certified by the company's Compensation Committee on February 12, 2025. Pursuant to the award, there remains 250,000 unvested performance stock options that are subject to a $15 stock price performance hurdle as described in the Papa Employment Agreement. Each performance stock option represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc. at the exercise price.